Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary thyroid lymphoma: The two ends of the spectrum.
Triantafillou E, Papadakis G, Tzaida O, Papazian M, Megalakaki A, Moustakas K, Keramidas I, Kaltzidou V, Tertipi A, Pappas A. Triantafillou E, et al. Among authors: tzaida o. J BUON. 2015 Jul-Aug;20(4):1164-8. J BUON. 2015. PMID: 26416071 Free article.
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Tzaida O, Gogas H, Dafni U, Kyroudi A, Papaspyrou I, Kyriakou V, Malamou-Mitsi V, Alamani M, Skopa C, Kostopoulos I, Kastritis E, Pectasides D, Briasoulis E, Kalofonos HP, Aravantinos G, Fountzilas G, Arapantoni-Dadioti P. Tzaida O, et al. Oncology. 2007;72(5-6):388-96. doi: 10.1159/000113148. Epub 2008 Jan 14. Oncology. 2007. PMID: 18187961 Clinical Trial.
gamma-H2AX: A potential biomarker in breast cancer.
Varvara PV, Karaolanis G, Valavanis C, Stanc G, Tzaida O, Trihia H, Patapis P, Dimitroulis D, Perrea D. Varvara PV, et al. Among authors: tzaida o. Tumour Biol. 2019 Sep;41(9):1010428319878536. doi: 10.1177/1010428319878536. Tumour Biol. 2019. PMID: 31552812 Free article.
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa C, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G. Malamou-Mitsi V, et al. Among authors: tzaida o. Ann Oncol. 2006 Oct;17(10):1504-11. doi: 10.1093/annonc/mdl147. Epub 2006 Sep 12. Ann Oncol. 2006. PMID: 16968874 Free article. Clinical Trial.
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G. Skarlos P, et al. Among authors: tzaida o. Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8. Cancer Chemother Pharmacol. 2012. PMID: 21901395
21 results